$0 co-pay?* Find out here4
Want to start? get the form4

  • What are people saying?

    Listen here.

    HEY MS

  • Meet folks in the know (one of their stories might inspire you).

    GUIDES

  • You're not alone (and we can prove it). Come connect with others.

    EVENTS

  • Find yours:

Number of people who have been prescribed GILENYA in the United States

30,583

For relapsing forms of multiple sclerosis (ms)

Novartis

ready to tell MS
where to go?

LEAVE YOUR MESSAGE ABOUT "HEY MS"

GILENYA® has a pregnancy registry—click here to learn more.

*In 2011, 98% of transactions for eligible people with commercial insurance had a $0 co-pay for GILENYA. People for whom GILENYA has been prescribed are required to report any benefits they receive through the GILENYA Prescription Co-Pay Support Program to their insurance company. This offer is not valid for prescriptions for which payment may be made in whole or in part under federal or state health programs, including but not limited to Medicare or Medicaid. This program is subject to termination or modification at any time.

†GILENYA can result in a slow heart rate when first taken. Your first dose will be given in a medical facility where you will be watched for at least 6 hours. If you stop taking GILENYA for more than 14 days after your first month of treatment, you will need to repeat this observation.

Every GILENYA Guide on our site is a GILENYA patient who has said, "HEY MS, Take This!" They have been compensated by Novartis for their involvement. Individual results may vary.

 
Join the "HEY MS" Conversation!
Novartis

We want you to come join us and share your voice, too

We will do our best to post your message promptly. Please know that while we are trying our best to share everyone's true feelings, unfiltered and unedited, we may not be able to post your message in part or in full.

If you take and upload a picture for your personal "HEY MS!" message, show us your attitude. Stick out your tongue, if you're feeling it.

While we may not be able to post every message, we're still listening. Before you proceed, please read our community guidelines:

  • Refrain from sharing any treatment and/or dosage information, as well as names of specific medicines (brand name or generic) and product manufacturers

  • No profane, indecent, or inappropriate language in your message or image, please (an obvious no-no)

  • Avoid using your e-mail address in your screen name or message, so this personal information remains private and protected

  • Do not include links to, or URLs, for other Web sites or social networks in your message

  • Limit your message to 140 characters

  • Your statement may be subject to modification, and your photo and statement may be used in other GILENYA® marketing materials

  • If you want to report a side effect from GILENYA, this isn't the place to do it.
    Call 1-888-NOW-NOVA (1-888-669-6682), or contact the FDA directly: visit www.fda.gov/medwatch or call 1-800-FDA-1088

 
 

I've read and agree to the guidelines.

AWESOME!
Novartis
SHARE: Novartis Novartis

THANKS FOR JOINING THE "HEY MS" CONVERSATION!

Now you're talking! Thanks for joining the movement and sharing your thoughts with us. Telling multiple sclerosis (MS) how you feel wasn't so difficult now, was it? Want to know when your message goes live?

As the conversation grows, we want to keep you informed. If you'd like to hear about new promotions, MS programs, and events, please check the box below.

I agree to receive marketing information, offers, and promotions about MS products and programs, and I'm willing to be contacted for my opinions on products, programs, and services.

The personal information you supply to us will be shared with and among our business partners to provide you with products, programs, and services regarding MS and to conduct market research. Your information will not be used by any of our business partners for their own separate marketing purposes. You have the right to cancel your participation at any time by calling 1-888-669-6682. For further information about Novartis privacy practices, please review our privacy policy.